Late-breaking data presented at THT shows substantial fluid loss and improvements in kidney and cardiac function at 30 days after Aortix therapy Cardiorenal syndrome (CRS) is a complex condition that impacts up to 40% of patients with acute decompensated heart failure and is growing at a double-digit rate HOUSTON, March 21, […]
Coronary/Structural Heart
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
12 Month Data Presented as Late-Breaking Clinical Science at THT 2023 and Simultaneously Published in the Journal of Cardiac Failure BOSTON–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement […]
Axon Therapies Cohort Study Extends Benefit to 6 months with Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
SANTA CLARA, Calif., March 22, 2023 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF. The latest data is consistent with prior results previously presented for their proprietary Splanchnic Ablation for Volume Management (SAVM) […]
V-LAP Allows Heart Failure Patients to Self-Adjust Medication: Vectorious Reports Promising Findings From its Pilot Study at the THT meeting
During 89.1% of the overall follow up duration (3504 days), Patient Self-Management (PSM) alone was sufficient to stabilize HF patients within the optimal LAP thresholds, while only 10.9% of follow up time, physician intervention was required to adjust medication TEL AVIV, Israel, March 22, 2023 /PRNewswire/ — Yesterday, Vectorious Medical Technologies Ltd. presented interim […]
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Patent provides intellectual property protection until December 2040 PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 There are currently no FDA approved treatments for PH-HFpEF Levosimendan combines two MoAs that, for the first time, specifically target the symptoms PH-HFpEF patients […]
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipid-lowering therapies in the pivotal trial TARRYTOWN, N.Y., March 22, […]
Nanox.AI Expands Footprint Through New Global Partnership with Ferrum Health
Partnership with Ferrum Health offers unprecedented data security and an integrated AI platform to streamline health systems’ adoption of AI technology, such as Nanox’s Bone solution (HealthOST) and cardiac solution (HealthCCSng) NEVE ILAN, Israel, March 22, 2023 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging […]
Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option […]
Mediwhale selected for the MedTech Accelerator program
South Korean AI health diagnostics startup is now working with three prestigious accelerator programs in the US Tempe, Ariz., USA, March 19, 2023 — Mediwhale, the AI-empowered health diagnostics company that uses retina scans to diagnose future cardiac and kidney disorder risk quickly and easily, will be heading to the […]
Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection
Clinical-grade biometric data flags chronic and acute diseases and disorders—assisting clinicians, improving health and wellness, and bettering lives ATLANTA, March 20, 2023 /PRNewswire/ — LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches […]



